The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksE-therapeutics Regulatory News (ETX)

Share Price Information for E-therapeutics (ETX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.50
Bid: 9.30
Ask: 9.95
Change: -0.25 (-2.56%)
Spread: 0.65 (6.989%)
Open: 9.55
High: 10.00
Low: 9.50
Prev. Close: 9.75
ETX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of share options and Directors' dealings

23 Nov 2016 16:21

RNS Number : 9836P
e-Therapeutics plc
23 November 2016
 

23 November 2016

 

e-Therapeutics plc

('e-Therapeutics' or 'the Company')

 

Grant of share options and Directors' dealings

 

Oxford and Newcastle, UK, 23 November 2016 - e-Therapeutics plc (AIM: ETX) the drug discovery company, announces that on 23 November 2016 the Company granted options over a total of 10,310,000 ordinary shares of 0.1p each to certain executive directors and other employees (the "Optionholders"). The Optionholders are entitled to exercise their options in three tranches (as set out below) on or after the date specified below, if, at the time of exercise, the prevailing market price of the Company's ordinary shares is not less than the price set out below (the "Exercise Price"). Optionholders will be required to pay the Exercise Price to exercise their options.

Number of shares under option Exercise Price Exercise Date

3,436,666 16.76p 23 November 2018

3,436,667 20.95p 23 November 2018

3,436,667 25.14p 23 November 2019

Details of the individual options granted to executive directors are set out below:

Director Number of shares under option

Steve Medlicott 2,000,000

Sean Nicolson 750,000

The options referred to above are otherwise subject to the Rules of the Company's 2013 Performance Share Plan. 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Steve Medlicott

2

Reason for notification

a.

Position/Status

Director

b.

Initial notification/

Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

e-Therapeutics plc

b.

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrumentIdentification Code

Ordinary shares of 0.1p each 

ISIN: GB00B2823H99

b.

Nature of the transaction

Grant of options to subscribe for ordinary shares

c.

Price(s) and volume(s)

 

 

 

 

 

 

Exercise price(s)

Volume(s)

 

£0.1676

666,666

 

 

£0.2095

666,667

 

 

£0.2514

666,667

 

 

d.

Aggregated information- Aggregated Volume

- Price

 

Volume: 2,000,000 options over ordinary shares

Price: N/A

e.

Date of the transaction

23 November 2016

f.

Place of the transaction

London Stock Exchange

         

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Sean Nicolson

2

Reason for notification

a.

Position/Status

Director

b.

Initial notification/

Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

e-Therapeutics plc

b.

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrumentIdentification Code

Ordinary shares of 0.1p each 

ISIN: GB00B2823H99

b.

Nature of the transaction

Grant of options to subscribe for ordinary shares

c.

Price(s) and volume(s)

 

 

Exercise Price(s)

Volume(s)

 

£0.1676

250,000

 

 

£0.2095

250,000

 

 

£0.2514

250,000

 

 

d.

Aggregated information- Aggregated Volume

- Price

 

Volume: 750,000

Price: N/A

e.

Date of the transaction

23 November 2016

f.

Place of the transaction

London Stock Exchange

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHLLFLRLTLVFIR
Date   Source Headline
7th Jun 20162:08 pmRNSIssue of Equity and Directors' shareholdings
1st Jun 20167:00 amRNSSearchbolt Offer becomes wholly unconditional
27th May 20163:18 pmRNSResult of General Meeting
25th May 20162:59 pmRNSResult of AGM
25th May 20167:00 amRNSAGM Statement
13th May 20164:08 pmRNSNotice of General Meeting - Correction
12th May 201610:50 amRNSDirector/PDMR Shareholding
11th May 20167:00 amRNSProposed Acquisition of Searchbolt, Notice of GM
15th Apr 201612:19 pmRNSNotice of AGM and Annual Report
22nd Mar 20167:00 amRNSFinal Results
4th Mar 20167:00 amRNSNotice of Results
15th Feb 20167:00 amRNSTop-line Phase IIb results update
6th Jan 20167:00 amRNSAppointment of Non-Executive Chairman
15th Dec 20153:38 pmRNSHolding(s) in Company
30th Nov 20154:48 pmRNSHolding(s) in Company
29th Oct 20157:00 amRNSAppointment of Non-Executive Director
29th Sep 20157:00 amRNSHalf Yearly Report
17th Sep 20157:05 amRNSNotice of Half Year Results
17th Sep 20157:00 amRNSChange of Nominated Adviser and Broker
10th Sep 20159:00 amRNSDirector's Disclosure
17th Aug 20157:00 amRNSHalf year trading and commercial strategy update
19th Jun 20158:38 amRNSExercise of Options
11th Jun 201511:31 amRNSResult of AGM
11th Jun 20157:00 amRNSAGM Statement
21st May 20157:00 amRNSProgress in ETS2101 Phase Ib Study
7th May 20157:00 amRNSNotice of AGM and Annual Report
31st Mar 20157:00 amRNSFinal Results
11th Mar 20154:08 pmRNSHolding(s) in Company
11th Mar 201512:41 pmRNSHolding(s) in Company
10th Mar 20157:03 amRNSNotice of Full Year Results
6th Mar 20152:22 pmRNSHolding(s) in Company
26th Feb 20151:55 pmRNSStmnt re Share Price Movement
21st Jan 201511:20 amRNSDirector/PDMR Shareholding
7th Jan 20157:00 amRNSAwards made under Performance Share Plan
7th Jan 20157:00 amRNSIssue of Equity
5th Jan 20157:00 amRNSDirectorate Change
19th Dec 20147:00 amRNSe-Therapeutics' Impact is rated World Class
18th Dec 20147:00 amRNSUpdate: ETS2101 Phase 1a and Oral Dosing Studies
27th Nov 20147:00 amRNSResearch and Development presentation to Investors
16th Oct 20148:35 amRNSAppointment of Executive Director
16th Sep 20147:00 amRNSHalf Yearly Report
4th Sep 20142:55 pmRNSNotice of Results
5th Aug 20147:00 amRNSAdditional Listing
1st Aug 20149:22 amRNSIssue of equity and Directors' shareholdings
9th Jul 201411:31 amRNSAGM Statement
9th Jul 20147:00 amRNSAwards made under Performance Share Plan
4th Jul 20147:00 amRNSDirector/PDMR Shareholding
27th Jun 20147:00 amRNSChange of Adviser
25th Jun 20144:11 pmRNSDirector/PDMR Shareholding
25th Jun 20143:57 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.